





USCOM



CARDIOLOGY PARTNER FOR U.S.

25 January 2005, USCOM Limited (ASX Code: UCM) today announced its principle North American partner in the field of cardiology.

The company has signed a collaborative agreement with the University of Arizona Medical Centre in Tucson for advanced research into the applications for USCOM in heart failure management, cardiac transplantation and post cardiac surgery.

Work has already begun on 4 separate studies, defining USCOM's role in clinical practice.

The University of Arizona Medical Centre is an internationally recognised centre of excellence in both clinical care and research. The hospital is among the best hospitals in the U.S. across nine areas of specialty medical care.

Among the studies being conducted is the application of USCOM alongside the CardioWest Total Artificial Heart, developed by Dr. Jack Copeland, Chief of Cardiovascular and Thoracic Surgery at the University Medical Centre and one of the world's leading heart surgeons.

The CardioWest device has been used as a bridge to transplant in more than 175 patients worldwide since its first use in 1983. The device was approved by the US Food and Drug Administration (FDA) in October 2004.

The first collaborative research with USCOM and CardioWest will be presented in March at the International Symposium on Intensive Care in Brussels, Belgium.

The paper concludes, *"This study confirms the accuracy of flow measurements using the USCOM device and the feasibility of non-invasive haemodynamic assessment of heart failure patients with artificial circulation."*

Commenting on the USCOM collaboration, Dr Copeland said, *"Cardiac Output is the most important information for the management of the post cardiac surgical patient. To be able to acquire that non-invasively, at no patient risk is even more important."*

USCOM's principle partner at Tucson is Dr Peter Lichtenthal, Associate Professor of Cardiothoracic Anaesthesia. Dr Lichtenthal said, *"USCOM has the potential to be a very important monitoring device, which can add a new dimension to the care of the patient with heart failure. We are looking forward to its US launch during 2005."*

USCOM submitted its application for FDA clearance in November 2004.

Commenting on the Tucson partnership, the Chairman of USCOM, Mr Rob Phillips said, *"We are honoured to have concluded a formal partnership with the University of Arizona team, who are world leaders in their field. The work we are doing in Tucson will form an important part of our US market entry. It will define the clinical utility of the USCOM device in the important clinical field of heart failure. Tucson will also serve as a centre of excellence reference site in cardiology."*